A single infusion of zorpocabt agene-autoleucel (Zorpo-cel), an autologous CAR T-cell therapy, has led to a rapid and sustained remission in a patient with multiple life-threatening autoimmune disorders, according to a newly reported case published in Med.
Researchers from the University Hospital of Erlangen at Friedrich-Alexander-Universitat Erlangen-Nürnberg in Germany describe how a CD19-targeting CAR T-cell therapy successfully treated a 47-year-old woman suffering from severe autoimmune hemolytic anemia (AIHA), along with immune thrombocytopenia (ITP) and antiphospholipid antibody syndrome (APLAS). All three conditions are driven by malfunctioning B cells that produce harmful autoantibodies attacking the body’s own tissues.
The patient’s condition had proven exceptionally difficult to manage. Over nearly a decade, she had undergone nine different treatment regimens, including steroids, immunosuppressants, and antibody-based therapies, without lasting success. Her AIHA was particularly severe, leaving her dependent on daily blood transfusions and at risk of organ damage due to chronic anemia and iron overload.
With no effective options remaining, the clinicians, under compassionate use, turned to the CAR T-cell therapy developed by Miltenyi Biomedicine. This technique involves collecting a patient’s own T cells, genetically modifying them to target the B cell marker CD19 and reinfusing them to eliminate the dysfunctional immune cells.
The results were striking. Within just seven days of treatment, the patient no longer required blood transfusions. By day 25, her hemoglobin levels had returned to normal, indicating a complete resolution of the hemolytic anemia. Laboratory markers of red blood cell destruction also normalized rapidly.
Equally notable was the therapy’s broader impact. The patient’s elevated antiphospholipid antibodies—responsible for dangerous blood clots in APLAS—fell to normal levels and remained undetectable through 11 months of follow-up. Meanwhile, her platelet counts stabilized, indicating improvement in ITP without the need for additional treatment.
Researchers attribute this success to a “reset” of the patient’s B cell population. Unlike conventional therapies such as rituximab, which partially deplete B cells, CAR T cells appear to achieve deeper and more durable elimination. When B cells eventually returned months later, they were predominantly naïve, suggesting a reprogrammed and healthier immune profile.
Importantly, the treatment was well tolerated. The patient experienced none of the serious side effects commonly associated with CAR T therapy in cancer patients, such as cytokine release syndrome or neurotoxicity. Some mild liver enzyme elevations and blood count abnormalities were observed, likely related to prior treatments and iron overload rather than the therapy itself.
This is the second clinical win for Zorpo-cel in the treatment of autoimmune diseases this year. In January, the Phase I/II basket trial known as the CASTLE trial reported encouraging early results of Zorpo-cel administration in 24 patients with treatment-resistant autoimmune diseases, including systemic lupus erythematosus (SLE), systemic sclerosis (SSc), and idiopathic inflammatory myopathies (IIM). The therapy showed a favorable safety profile, with no cases of severe cytokine release syndrome or neurotoxicity observed. Efficacy outcomes were strong: 22 of 24 patients met predefined endpoints, including remission in most SLE patients, halted disease progression in all SSc patients, and meaningful clinical responses in the majority of IIM cases.
The case highlights the growing potential of CAR T therapy beyond oncology. Previous studies have shown promising results in systemic autoimmune diseases like lupus, but evidence in hematologic autoimmune disorders such as AIHA has been limited. While the findings are encouraging, researchers caution that this is a single case report. Larger, controlled clinical trials will be necessary to confirm safety, effectiveness, and long-term outcomes across diverse patient populations.
The post CAR T Cells Drive Recovery in Severe Autoimmune Disease Case appeared first on Inside Precision Medicine.